Is SSRSF or JNJ a better dividend investment in 2026?

SSRSF currently yields 2941.18% with a 5% 5-year dividend growth rate. JNJ yields 2.13% with 5.8% growth. The better choice depends on your goal: SSRSF offers higher current income.

What is the dividend yield difference between SSRSF and JNJ?

SSRSF has a forward dividend yield of 2941.18% ($2.00/share annually). JNJ yields 2.13% ($5.20/share annually). The yield gap is 2939.05 percentage points.

Home › Compare › SSRSF vs JNJ

SSRSF vs JNJ: Dividend Comparison 2026

SSRSF yields 2941.18% · JNJ yields 2.13%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 SSRSF wins by $376478797989.55M in total portfolio value

INVESTMENT

TIME HORIZON10 years

SSRSF

● Live price

2941.18%

Share price

$0.07

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$376478797989.58M

Annual income

$352,877,256,847,591,550.00

Full SSRSF calculator →

JNJ

Johnson & Johnson

● Live price

2.13%

Share price

$244.44

Annual div

$5.20

5Y div CAGR

28%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$30.3K

Annual income

$4,689.40

Full JNJ calculator →

Portfolio growth — SSRSF vs JNJ

📍 SSRSF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	SSRSF	JNJ
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, SSRSF + JNJ cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

SSRSF pays

JNJ pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SSRSF

Annual income on $10K today (after 15% tax)

$250,000.00/yr

After 10yr DRIP, annual income (after tax)

$299,945,668,320,452,800.00/yr

JNJ

Annual income on $10K today (after 15% tax)

$180.82/yr

After 10yr DRIP, annual income (after tax)

$3,985.99/yr

At 15% tax rate, SSRSF beats the other by $299,945,668,320,448,830.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SSRSF + JNJ for your $10,000?

SSRSF: 50%JNJ: 50%

100% JNJ50/50100% SSRSF

Portfolio after 10yr

$188239398994.81M

Annual income

$176,438,628,423,798,100.00/yr

Blended yield

93.73%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

SSRSF

No analyst data

Altman Z

-832.0

Piotroski

1/9

JNJ

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$228.73

-6.4% upside vs current

Range: $190.00 — $265.00

Altman Z

5.2

Piotroski

4/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SSRSF buys

JNJ buys

No recent congressional trades found for SSRSF or JNJ in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricSSRSFJNJ

Forward yield	2941.18% ✓	2.13%
Annual dividend / share	$2.00	$5.20 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	28% ✓
Portfolio after 10y	$376478797989.58M ✓	$30.3K
Annual income after 10y	$352,877,256,847,591,550.00 ✓	$4,689.40
Total dividends collected	$374845278006.75M ✓	$15.4K
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare

Year-by-year: SSRSF vs JNJ ($10,000, DRIP)

Year	SSRSF Portfolio	SSRSF Income/yr	JNJ Portfolio	JNJ Income/yr	Gap
1← crossover	$304,818	$294,117.65	$10,592	$272.30	+$294.2K → SSRSF
2	$8,704,870	$8,378,714.87	$11,289	$357.73	+$8.69M → SSRSF
3	$232,936,869	$223,622,657.89	$12,123	$472.89	+$232.92M → SSRSF
4	$5,841,768,074	$5,592,525,624.47	$13,141	$629.86	+$5841.75M → SSRSF
5	$137,328,835,762	$131,078,143,923.34	$14,408	$846.81	+$137328.82M → SSRSF
6	$3,026,752,499,651	$2,879,810,645,385.39	$16,021	$1,151.60	+$3026752.48M → SSRSF
7	$62,557,830,808,735	$59,319,205,634,108.02	$18,122	$1,588.22	+$62557830.79M → SSRSF
8	$1,212,756,672,759,447	$1,145,819,793,794,100.50	$20,930	$2,228.20	+$1212756672.74M → SSRSF
9	$22,057,515,085,970,270	$20,759,865,446,117,664.00	$24,792	$3,191.91	+$22057515085.95M → SSRSF
10	$376,478,797,989,579,800	$352,877,256,847,591,550.00	$30,274	$4,689.40	+$376478797989.55M → SSRSF

SSRSF vs JNJ: Complete Analysis 2026

SSRSF — Stock

Silver Sands Resources Corp. engages in the acquisition and exploration of mineral resource properties in Canada. It holds 100% interest in the Virginia silver project located in Santa Cruz Province of Argentina; and an interest in the Corner Pocket copper-zinc-silver massive sulfide project covering an area of 6,400 hectares located in Newfoundland. The company was formerly known as Golden Opportunity Resources Corp. and changed its name to Silver Sands Resources Corp. in June 2020. Silver Sands Resources Corp. was incorporated in 2018 and is based in Vancouver, Canada.

Full SSRSF Calculator →

JNJ — Healthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →

📬

Get this SSRSF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SSRSF vs SCHD SSRSF vs JEPI SSRSF vs O SSRSF vs KO SSRSF vs MAIN SSRSF vs ABBV SSRSF vs MRK SSRSF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.